PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16740972-8	2006	Treatment of cytochalasin-D-treated cells with hormones and dbcAMP resulted in an increase in the secretion of IGF-binding protein-1 (IGFBP-1) and prolactin.	Bucladesine	60-66	prolactin	Homo sapiens	147-156	
17272923-4	2007	When treated with the decidual stimulus dibutyryl-cAMP (db-cAMP) or forskolin, the fibroblastic cell-shaped EtsT cells transformed into large- and round-shaped cells and secreted large amounts of the decidual markers prolactin (PRL) and insulin-like growth factor binding protein-1 (IGFBP-1).	Bucladesine	40-54	prolactin	Homo sapiens	228-231	
17272923-4	2007	When treated with the decidual stimulus dibutyryl-cAMP (db-cAMP) or forskolin, the fibroblastic cell-shaped EtsT cells transformed into large- and round-shaped cells and secreted large amounts of the decidual markers prolactin (PRL) and insulin-like growth factor binding protein-1 (IGFBP-1).	Bucladesine	56-63	prolactin	Homo sapiens	228-231	
17272923-7	2007	It also abolished db-cAMP-induced PRL and IGFBP-1 mRNA expression and protein secretion.	Bucladesine	18-25	prolactin	Homo sapiens	34-37	
16690806-3	2006	Treatment of human endometrial stromal cells with hormones (estradiol and medroxyprogesterone acetate) plus dibutyryl cAMP (H+dbcAMP) for 48 h increased expression of IGFBP1, PRL, TIMP3, CNR1, and DCN but not LAMB1, as measured by real-time PCR.	Bucladesine	126-132	prolactin	Homo sapiens	175-178	
8404671-2	1993	PRL production under these conditions was demonstrated by documenting the synthesis of PRL mRNA (approximately 1.1 kilobase), the output of immunoprecipitable [35S]methionine-labeled PRL migrating as a single 23-kilodalton band during gel electrophoresis, and the time- and concentration-dependent secretion of PRL into the medium, measured by RIA (maximal on days 4-5 using 0.5 mM db-cAMP).	Bucladesine	382-389	prolactin	Homo sapiens	0-3	
8752665-5	1996	Dibutyryl-cyclic AMP, a second messenger in prostaglandin signal transduction, was also synergistic with medroxyprogesterone acetate and E2, but induced significant PRL expression in the absence of the steroids (28 and 12 ng/72 h, respectively).	Bucladesine	0-20	prolactin	Homo sapiens	165-168	
8752665-6	1996	The increase in PRL release was not a result of increased cell proliferation, because the PRL-secreting cultures had 32.2 +/- 8.8% less DNA (N = 3 individuals, 93% confidence limit) than control cultures after 3 weeks of treatment with dibutyryl-cyclic AMP, medroxyprogesterone acetate, and E2.	Bucladesine	236-256	prolactin	Homo sapiens	16-19	
8752665-6	1996	The increase in PRL release was not a result of increased cell proliferation, because the PRL-secreting cultures had 32.2 +/- 8.8% less DNA (N = 3 individuals, 93% confidence limit) than control cultures after 3 weeks of treatment with dibutyryl-cyclic AMP, medroxyprogesterone acetate, and E2.	Bucladesine	236-256	prolactin	Homo sapiens	90-93	
8404671-3	1993	Medroxyprogesterone acetate (1 microM) enhanced (1.7- to 2.5-fold) the effect of db-cAMP, 8-bromo-cAMP, or forskolin on PRL production, as evaluated by Western blotting analysis.	Bucladesine	81-88	prolactin	Homo sapiens	120-123	
2482208-5	1989	The addition of dibutyryl cAMP caused a minor transient increase in hPRL secretion by 35% after 1 h.	Bucladesine	16-30	prolactin	Homo sapiens	68-72	
2985726-2	1985	High K+ concentrations, hypothalamic extract, synthetic thyrotrophin-releasing hormone (TRH) and dibutyryl cyclic AMP (dbcAMP) all stimulated release of prolactin from control (non EGTA-treated) hemianterior pituitary glands.	Bucladesine	119-125	prolactin	Homo sapiens	153-162	
2985726-8	1985	Although influx from the medium may be the major source of Ca2+, endogenous stores of Ca2+, perhaps mobilized by dbcAMP, may be able to maintain some release of prolactin.	Bucladesine	113-119	prolactin	Homo sapiens	161-170	
2438170-1	1987	Exposure of human decidual cells for 0.5 h to dibutyryl cAMP, isobutyl-methylxanthine (IBMX), cholera toxin or forskolin caused a dose-dependent inhibition of prolactin release with maximal inhibition by each agent of 50-60%.	Bucladesine	46-60	prolactin	Homo sapiens	159-168